Generics 1

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Deferasirox manufacturers

1 products found

Filters

Filters

Filters , active

Country of origin : Malaysia

Clear all

1 products found

deferasirox

Tablets, immediate release (IR) 90 mg, 180 mg, 360 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Malaysia
GMP approvals
WHO, PICS, MY
Unavailable markets
Brunei , Malaysia , Singapore
Available for
Licensing with supply, Distribution only, Technology transfer
Manufacturer #25654
This company is a global pharmaceutical player with over three decades of experience, focusing primarily on oncology products. They boast manufacturing facilities in Malaysia, Uzbekistan, and Pakistan, all adhering to stringent regulatory standards like USFDA, NPRA, PIC/S, and UAE MoHAP. Their product portfolio includes prescription medications like Pazopanib Tablets, Trametinib, Sunitinib, and Gefitinib, among others. They also offer over-the-counter drugs and possess Halal certifications for select products. The company emphasizes R&D, with a dedicated oncology center in Malaysia, and engages in strategic collaborations for in-licensing, out-licensing, tech transfer, contract development, and manufacturing.

Manufacturer usually replies in 3 days

Want to see all 1 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Deferasirox Manufacturers

Deferasirox is an iron chelator belonging to a class of medications called Iron-Chelating agents. Deferasirox is the first oral medication approved by FDA for chronic iron overload in patients receiving blood transfusion for a prolonged use and this medication is also used to treat high levels of iron in people with certain blood disorders who actually do not require blood transfusion. Blood transfusion is often needed in few types of blood diseases such as anemia, sickle cell disease, which leads to additional iron that may build up in the body and cause problems such as diabetes, liver disease, heart failure etc, and deferasirox is used to eliminate the additional iron from the bloodstream and reduces the risk of these diseases.

Before using deferasirox, the risk of taking the drug must be weighed against the benefits it provides. It is always recommended to consult a physician before taking deferasirox as this medication may interact with other drugs or health problems.

Deferasirox is advised as a prescription product as well as generic prescription product. Manufacturers market deferasirox under the Brand name of Exjade, Jadenu. Deferasirox is available in a dosage form of tablet, granules, tablet for suspension in dosage strengths of 90 mg, 125 mg, 250 mg, 500 mg which is taken by mouth once daily on an empty stomach half an hour before meals. Deferasirox tablets are supplied as round, white, film coated tablets imprinted with the first letter of brand name and strength on one side and manufacturer name on the other side in a bottle of 30 tablets.

Deferasirox therapy should be considered only when a patient has proof of iron overload over a long-term blood transfusion, the recommended initial dose of deferasirox in transfusional iron overload patients with 2 years of age and older with estimated glomerular filtrate rate greater than 60 mL/min/1.73 m2 is 20 mg per kg body weight given orally once daily. The recommended initial dose of deferasirox in iron overload in non-transfusion-dependent thalassemia syndromes in patients with eGFR greater than 60 mL/min/1.73 m2 is 10 mg per kg body weight given orally once daily. Deferasirox Tablets are recommended to be stored at 25° C (77° F), in well closed containers with excursions permitted to 15° C to 30° C (59° F to 86° F) with protection from moisture.

Wholesale Price of Deferasirox

The wholesale price for 30 units of 90 mg deferasirox oral tablet is $ 966 with per unit cost comes at $ 32.21 The cost for deferasirox 180 mg oral tablet is around $ 1922 for a supply of 30 tablets with per unit cost available for as low as $ 64 The cost for deferasirox oral granule for reconstitution 90 mg is around $ 914 for a supply of 30 tablets with per unit cost available for as low as $ 30.47

Deferasirox - Mechanism of Action

Deferasirox works by binding to iron in the bloodstream by forming a stable complex which is eliminated through kidneys.

Finding Deferasirox Manufacturers and Suppliers

To find a trustful partner in any business is one of the tedious tasks and to overcome that challenge and to make one’s work / life easy in finding the trustful and suitable manufacturer and supplier of Deferasirox one can visit the Pipelinepharma website which helps the buyer in finding the dependable manufacturers and suppliers of Deferasirox. Pipelinepharma, which is a business-to-business (B2B) licensing marketplace for pharmaceutical products, quickly connects owner with the buyer for the business advancement. One can filter the product names in unified search engine by its country, category, therapeutic area, forms, dossier and its status, regulatory filings, approvals, and many more.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation